The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The way AIM works is that institutions don't buy in the market. they buy on these placings in size at a discounted price.
Rule 2 on AIM is that private investors get ripped off continually by this process and subsequent dilution.
Anyway the Miton and Canaccord news is positive....quite simply they would not have backed the placing if they didn't like the story.
Well the share price does seem too low for what they have. Clearly the market is as much interested in the financing of the company going forward as the clinical results. Trouble is PIs may be burnt and institutions don't seem interested in investing in the smaller end of the market.
The days when UK fund managers held 50/60% of their money in UK equities seem a distant memory.
You would think it would be a great time for an institution to take an interest. Tremendous validation by well known blue chip names in terms of manufacturing capability. This leading global distributor is obviously convinced cpx can supply in the right volumes at the correct quality post the shift to Aus production.
I am certain Conti would have done enough research on Cpx to be very comfortable with their ongoing viability/financial status/production capability. I know this from talking to various parties over the years on similar deals. They would hardly want their own production run to be halted by problems with supply from a tiny company in Australia!
I'm maybe secretly hoping that Conti might just think it best to buy out Cpx for say 50p per share..ha ha
It would be useful to have some indication of whether CPX can supply from existing capacity in Sydney. What is the present capacity utilization? Maybe there is info out there and I have forgotten.
If automotive is to become a mainstay (along with IOT) then it would make sense to have some production capacity in Europe (Germany). The likes of Conti could fund this in exchange for ongoing royalty payments or some sort of deal.
I think sometimes AK lacks the vision to seize all the opportunities that are out there.
That's right. The release will have been cleared by Conti as well. But it's undoubtedly a great approval and endorses CPX systems and processes AND quality. Tier 1 OEM automotive is as good as it gets in terms of product validation.
I think you need to think this through a bit more parkez. I totally disagree with what you are saying.
Firstly as things stand a win over Maxwell would be icing on the cake...quite a lot of icing.
Your view of 'make or break' might have been more relevant to the old CPX which was highly reliant on licencing/royalty income.
The company is now a manufacturer with a growing niche product line and a strong order book. Have a re-read of the recent interim results. The statement from the company about suitable terms on litigation funding is based on not wanting to hand over half of the winnings. CPX has cash and no debt and can afford to see through to the end of the litigation. It may be resolved before the trial date in July.
This company has been mired by incompetent management for years. No matter what happens to the £/$/Euro /Ethiopian thingy...they seem to lose out. Year after year these mugs manage to **** it up.
I'm not sure anyone hopes/hoped the company would not succeed. The issue though for many was that the ceo seemed to reward himself massively with share sales/salary/bonus and that became the single biggest issue (putting a stop to reward for failure).
Sorry for any holders here. I think events like this will recur unless there are stiffer penalties for wrongdoing. Whatever happened at Patisserie Valerie for eg... Have heard nothing about punishment for the wrong doers. In this case I can scarcely believe that this is all down to one individual. Even basic financial control must have been lacking. For any contract you need proper DD to assess its veracity..
Just been looking at Skeleton. Founded in 2009 in Estonia and now just building the largest supercap plant in the world in Dresden Germany. Meanwhile CPX lurches from one disaster to the next and is valued at £15m. A painful comparison.